To further verify the role of our five-CMG signature (ABCA1, TSPO, NCEH1, NR1H3 and HMGCR) in predicting the response to immunotherapy, we retrospectively enrolled 35 GC patients treated with a PD-1 inhibitor. The gene discussed is NR1H3; the disease is gastric cancer.